Eric Greenberg

Contributing Editor, Packaging World

What Do PFAS Actions Tell Us About Food Contact Substances Industry?

The PFAS story keeps developing, and isn’t over yet.

Why Would FDA’s Emergency Actions Stick Around After the Emergency is Over?

While some of the Food and Drug Administration’s actions in response to COVID-19 have been traditional, many others have been simplifications of regulatory requirements, and those simplifications could be made permanent.

We’re All Apart, and All Together

You don’t need me to tell you that the pandemic is creating a weird situation.

Tales From the Front: Packaging Environment a Hotbed of Activity

In the world of environmental pressures on packaging, signs are pointing more strongly in both directions: Industry efforts and messaging are becoming more powerful.

More from Eric Greenberg

Updating the Nutrition Facts Panel: Easier Said Than Done, for Packagers and FDA

That specially formatted rectangular box with “Nutrition Facts” in bold letters across the top is the single most recognizable feature of a packaged food label.

Feds Say Not Legal, But Still It’s Not Rare: Why’s CBD for Sale Everywhere?

In our column’s continuing effort to correct common misconceptions about packaging law, this month we turn to cannabidiol, or CBD.

You Are Wrong About Nutraceuticals, Functional Foods, and Dietary Supplements. But I Will Explain.

Lawyers love to tell people they are wrong.

Laws and Norms Both Shape Policy

When you go to someone’s house for dinner, you’re supposed to bring a gift.

Changes in Homeopathic Drugs Lead FDA to Change Policy

Attention, homeopathic drug packagers: The Food and Drug Administration has a new attitude toward you.

Caution: Environmental Pressures on Packaging Persist

As the kids say, the current worldwide anti-plastics and anti-packaging trend is “a thing.”

Cannabis Research Lights Finally Turn Green

DEA makes a move to help increase the availability of cannabis for medical research.

Companies Stay Alert as There’s No Obvious Slowing at FDA

One might expect these to be sleepy times at the U.S. Food and Drug Administration, seeing as how its commissioner resigned in spring, and that it’s part of an administration that has a dogmatically anti-regulatory philosophy.

Eric F. Greenberg

For Opioid Solutions, the Law Points to Packaging

FDA singles out a specific form of drug packaging in a proposed part of its efforts to stem the tide of opioid addiction.